COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00117351
Recruitment Status : Terminated (insufficient efficacy)
First Posted : July 6, 2005
Last Update Posted : February 17, 2011
Information provided by:
Millennium Pharmaceuticals, Inc.

Brief Summary:
This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Adenocarcinoma, Bronchiolo-Alveolar Drug: VELCADE Phase 2

Detailed Description:
Bronchioloalveolar carcinoma (BAC) and adenocarcinoma with bronchioloalveolar features are distinct subtypes of non-small-cell lung cancer which are difficult to treat in advanced stages. This study will determine the safety and efficacy of VELCADE therapy in patients with advanced BAC or adenocarcinoma with BAC features who have failed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Phase 2 Study of VELCADE (Bortezomib) for Injection in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma With Bronchioloalveolar Features
Study Start Date : April 2005
Actual Primary Completion Date : June 2007
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Bortezomib

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have histologically or cytologically confirmed BAC or adenocarcinoma with BAC features.
  • Have stage IIIB (malignant pleural effusion) or stage IV disease.
  • Have progressed on or after receipt of 1 to 2 prior lines of chemotherapy, one of which must be an EGFR TKI (Iressa or Tarceva). Adjuvant chemotherapy will NOT be counted as a prior line of therapy.
  • Have radiographic documentation of progressive disease (PD) as determined by the investigator.
  • Have measurable disease by RECIST.
  • Are 18 years of age or older.
  • Have a life expectancy greater than 3 months.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  • Are able to provide written informed consent in accordance with all applicable regulations and follow the study procedures.
  • Patients must be capable of understanding the investigational nature and potential risks and benefits.

Exclusion Criteria:

  • Have had chemotherapy (or an EGFR TKI) 4 weeks prior to enrollment.
  • Have peripheral neuropathy of Grade 2 or greater intensity, as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 3.0).
  • Have been previously treated with VELCADE.
  • Have experienced myocardial infarction within 6 months prior to enrollment or have New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  • Have had radiation therapy within 4 weeks prior to enrollment.
  • Have had monoclonal antibody therapy within 4 weeks prior to enrollment.
  • Have had any major surgery within 4 weeks prior to enrollment.
  • Have inadequate organ function at the Screening visit as defined by laboratory testing
  • Have symptomatic brain metastases or brain metastases that have not responded to radiation therapy, local or systemic chemotherapy, or were not completely resected by stereotactic surgery or other surgical modalities, or have significant post treatment brain edema.
  • Have uncontrolled active systemic infection requiring treatment.
  • Have had treatment for a cancer other than BAC within 5 years prior to enrollment, with the exception of basal cell carcinoma or cervical cancer in situ.
  • Have a history of allergic reaction attributable to compounds containing boron or mannitol or hypersensitivity reactions to drugs formulated with polysorbate 80.
  • Have known human immunodeficiency virus (HIV)-positive or hepatitis B surface antigen-positive status or known active hepatitis C infection. Patients assessed by the investigator to be at risk for HIV, hepatitis B or C infection should be tested in accordance with local regulations.
  • Have poorly controlled hypertension, diabetes mellitus, or another serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  • Are a pregnant or breast-feeding female. Confirmation that the patient is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during the screening period. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
  • Are unwilling to employ adequate means of contraception (condoms, diaphragm, birth control pills, injections, intrauterine device, or abstinence).
  • Are currently receiving or have previously received an investigational agent for any reason within 4 weeks of enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00117351

Layout table for location information
United States, Washington
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Layout table for additonal information Identifier: NCT00117351    
Obsolete Identifiers: NCT00119223
Other Study ID Numbers: C05002
First Posted: July 6, 2005    Key Record Dates
Last Update Posted: February 17, 2011
Last Verified: February 2011
Keywords provided by Millennium Pharmaceuticals, Inc.:
Carcinoma, Bronchioloalveolar
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchiolo-Alveolar
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Adenocarcinoma, Bronchiolo-Alveolar
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Adenocarcinoma of Lung
Antineoplastic Agents